⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Official Title: The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.

Study ID: NCT00376883

Interventions

pamidronate

Study Description

Brief Summary: Multiple myeloma is a malignant hematological disease dominated by monoclonal plasma cells in the bone marrow. Major symptoms are related to the bones due to an increased bone resorption and a decreased bone formation leading to bone pain and increased risk of fractures. The normal osteoclasts are responsible for bone degradation through stimulation from the malignant plasma cells. Bisphosphonates have been shown to inhibit the osteoclast activity but may have serious side-effects due to renal toxicity and the optimal dose have not been established. In a randomized double blinded design it is aim to compare the standard of monthly injections of 90 mg pamidronate with 30 mg. The primary end-point is physical function estimated by EORTC QLQ-C30 questionnaire at 12 months after starting the treatment in newly diagnosed treatment demanding multiple myeloma. Secondary end-points are skeletal related events, cost-utility analysis, response, response duration and survival and quality of life with respect to fatigue and pain.

Detailed Description: Patients with newly diagnosed treatment demanding multiple myeloma are after informed consent and approved inclusion criteria randomised by telephone call to Copenhagen Trial Unit (CTU) and information on the target dose is send to the distributor, Amgros, and the local pharmacy for preparation of the pamidronate solution. Infusion is given for 2½ hours. Before starting treatment the patient has to fulfil the first EORTC QLQ-C30 questionnaire that is send to the quality of life secretariat in Oslo, Norway. Subsequent questionnaires are mailed directly to the patients every third month. The infusions are continued for 3 years and may be extended further upon the patient's request. Every third month the number of skeletal event, the response and complications are recorded. Skeletal X-rays are performed 9 and 24 months after starting the treatment.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Department of Haematology B, Aalborg Hospital, University of Aarhus, Aalborg, , Denmark

Department of Haematology, Herlev University Hospital, Herlev, , Denmark

Department of Hematology L, Rigshospitalet, København Ø, , Denmark

Hæmatologisk afd., Århus Universitetshospital, Århus, , Denmark

Hematologisk seksjon, med avd, Haukeland Universitetssykehus, Bergen, , Norway

Hematologisk avdeling Ullevål Sykehus, Oslo, , Norway

Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge, Tromsø, , Norway

Hematologisk seksjon, St.Olav Hospital, Trondheim, , Norway

Sahlgrenska Universitetsjukhuset Östra, Gothenburg, , Sweden

Hematologkliniken, Universitetssjukhuset, Linköping, , Sweden

Medicinklin, Universitetssjukhuset MAS,, Malmö, , Sweden

Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus, Umeå, , Sweden

Medicinklinikken Akademiska sjukhuset, Uppsala, , Sweden

Medicinkliniken, Universitetssjukhuset, Örebro, , Sweden

Contact Details

Name: Peter Gimsing, Ass. prof.

Affiliation: Nordic Myeloma Study Group

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: